Quick Answer
Tenaya Therapeutics, Inc. reported Research And Development Expense of $68.61 million for the year ending 2025.
- Tenaya Therapeutics, Inc. showed a decrease of -20.9% in Research And Development Expense from 2024 to 2025.
- This data is from Tenaya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $6.96 million | Q3 2020: $8.48 million | Q1 2021: $9.59 million | Q2 2021: $10.91 million | Q3 2021: $12.94 million | Q1 2022: $24.16 million | Q2 2022: $20.88 million | Q3 2022: $23.76 million | Q1 2023: $25.61 million | Q2 2023: $26.48 million | Q3 2023: $23.09 million | Q1 2024: $25.06 million | Q2 2024: $22.65 million | Q3 2024: $20.35 million | Q1 2025: $21.08 million | Q2 2025: $17.37 million | Q3 2025: $15.36 million.
- Over the full 6 years of available data (2020 to 2025), Tenaya Therapeutics, Inc.'s Research And Development Expense has grown by 120.6%.
- Historical annual values: Fiscal year 2025: $68.61 million | Fiscal year 2024: $86.74 million | Fiscal year 2023: $98.04 million | Fiscal year 2022: $94.54 million | Fiscal year 2021: $54.39 million | Fiscal year 2020: $31.10 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: